Literature DB >> 22565577

Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29.

Monika Kwiecinski1, Natalia Elfimova, Andrea Noetel, Ulrich Töx, Hans-Michael Steffen, Ulrich Hacker, Roswitha Nischt, Hans Peter Dienes, Margarete Odenthal.   

Abstract

MicroRNAs are short noncoding, endogenous RNA species that posttranscriptionally inhibit gene expression by targeting the untranslated region (UTR) of mRNAs. Recently, it was shown that miR-29 inhibits expression of extracellular matrix proteins such as collagens, suggesting an antifibrotic function of miR-29. In the present study, we now investigated the role of miR-29 in profibrogenic growth factor expression as a further central mechanism of fibrosis. Screening of databases revealed putative miR-29 target sequences in the mRNA of platelet-derived growth factor (PDGF)-B, PDGF-B receptor, PDGF-C, vascular endothelial growth factor-A, and insulin-like growth factor (IGF)-I. To analyze miR-29 interaction with the predicted binding sites, we cloned the 3'-UTR sequences of the putative targets in fusion to the luciferase-reporter coding sequence. Functional miR-29 binding to PDGF-C and IGF-I mRNA sequences, but not to the corresponding mutants, was then proven by reporter assays. Hepatic stellate cells (HSC) that transdifferentiate into myofibroblasts, producing extracellular matrix proteins and profibrogenic growth factors, for example, the members of the PDGF family, are crucial for liver fibrosis. Myofibroblastic transition of primary HSC resulted in the loss of miR-29, but in a significant increase of PDGF-C and IGF-I. Compensation of reduced miR-29 levels by miR-29 overexpression in myofibroblastic HSC was followed by a definitive repression of IGF-I and PDGF-C synthesis. After experimental fibrosis, induced by bile-duct occlusion, miR-29 expression was shown to be reduced, but IGF-I and PDGF-C expression was upregulated, correlating inversely to the miR-29 pattern. Thus, we conclude that miR-29, downregulated during fibrosis, acts as an antifibrogenic mediator not only by targeting collagen biosynthesis, but also by interfering with profibrogenic cell communication via PDGF-C and IGF-I.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22565577     DOI: 10.1038/labinvest.2012.70

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  35 in total

1.  A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF.

Authors:  Kexiang Zhang; Chaoyue Zhang; Li Liu; Jiahui Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  Hepatobiliary quiz-8 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-12

3.  The diverse roles of the TNF axis in cancer progression and metastasis.

Authors:  Boram Ham; Maria Celia Fernandez; Zarina D'Costa; Pnina Brodt
Journal:  Trends Cancer Res       Date:  2016-01-01

4.  MicroRNA 29 targets nuclear factor-κB-repressing factor and Claudin 1 to increase intestinal permeability.

Authors:  QiQi Zhou; Stefan Costinean; Carlo M Croce; Alan R Brasier; Shehzad Merwat; Scott A Larson; Sarpreet Basra; G Nicholas Verne
Journal:  Gastroenterology       Date:  2014-09-30       Impact factor: 22.682

5.  The mechanisms of HSC activation and epigenetic regulation of HSCs phenotypes.

Authors:  Agata Page; Derek A Mann; Jelena Mann
Journal:  Curr Pathobiol Rep       Date:  2014-09-27

6.  MiR-29a Assists in Preventing the Activation of Human Stellate Cells and Promotes Recovery From Liver Fibrosis in Mice.

Authors:  Yoshinari Matsumoto; Saori Itami; Masahiko Kuroda; Katsutoshi Yoshizato; Norifumi Kawada; Yoshiki Murakami
Journal:  Mol Ther       Date:  2016-06-23       Impact factor: 11.454

7.  MicroRNAs in Liver Disease: Bench to Bedside.

Authors:  Nihar Shah; James E Nelson; Kris V Kowdley
Journal:  J Clin Exp Hepatol       Date:  2013-09-17

Review 8.  Review of microRNA in osteosarcoma and chondrosarcoma.

Authors:  Le Chang; Swati Shrestha; Greg LaChaud; Michelle A Scott; Aaron W James
Journal:  Med Oncol       Date:  2015-04-26       Impact factor: 3.064

9.  Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis.

Authors:  Zhen Chen; Tsung-Ching Lai; Yi-Hua Jan; Feng-Mao Lin; Wei-Chi Wang; Han Xiao; Yun-Ting Wang; Wei Sun; Xiaopei Cui; Ying-Shiuan Li; Tzan Fang; Hongwei Zhao; Chellappan Padmanabhan; Ruobai Sun; Danny Ling Wang; Hailing Jin; Gar-Yang Chau; Hsien-Da Huang; Michael Hsiao; John Y-J Shyy
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

Review 10.  MicroRNAs in liver disease.

Authors:  Gyongyi Szabo; Shashi Bala
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-05-21       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.